Taiwain Expects To Use U.S. A/H1N1 Flu Sample To Produce Own Vaccine
This article was originally published in PharmAsia News
Executive SummaryTaiwan expects to have a locally developed version of an A/H1N1 vaccine ready by September, drawing on U.S. samples provided to produce a seed stock. Taiwan is having its National Research Institute study the viral samples to watch for mutations. The World Health Organization is expected to ship other samples of the virus strain by the end of May to develop a vaccine. (Click here for more
You may also be interested in...
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.